Featured Clinical Trials
Learn what’s coming down the research pipeline, and find breast cancer clinical trials you may be eligible to participate in.
A clinical trial seeks 880 participants to test whether removing the tumor in the breast in newly diagnosed metastatic breast cancer helps women who receive systemic therapy to live longer than those who receive systemic therapy alone.
The new SystHERs (Systematic Therapies for HER2 positive Metastatic Breast Cancer Study) Registry seeks to enroll 1,000 people with HER2 positive metastatic breast cancer to analyze treatment patterns and outcomes.
Researchers seek 4,000 participants for a clinical trial that will study whether hormonal therapy alone is adequate treatment for early-stage invasive breast cancer that traveled to one to three axillary lymph nodes and is found to be of low or intermediate risk for recurrence by genomic tests.
A research study on immune response and suppression in different types of breast cancer seeks women diagnosed between the ages of 18 and 49 anywhere in the U.S.
A phase II clinical trial is examining how well four neoadjuvant therapy (treatment before surgery) combinations of chemotherapy and bevacizumab (Avastin) work in treating women with triple-negative breast cancer that can be removed by surgery.
Premenopausal women who are newly diagnosed with breast cancer and have not yet had chemotherapy are needed to participate in a study looking at biological factors that may relate to ovarian insufficiency after chemotherapy.
Researchers are seeking to find out if hormonal therapy with tamoxifen affects ovarian function and age of menopause onset in women with breast cancer.
A phase III clinical trial evaluates trastuzumab emtansine (TDM-1), a new type of HER2-targeted therapy, in participants with HER2 positive metastatic breast cancer that stopped responding to treatment.
If you are affected by triple-negative breast cancer or have HER2 negative breast cancer with BRCA1/2 mutations, find out if you are eligible to participate in this trial, which is considering the impact of rucaparib, a PARP inhibitor on stages I-III breast cancer.
If you are affected by early-stage breast cancer that has been indicated to have a high risk of recurrence, find out whether you are eligible to participate in the D-CARE clinical trial, which is considering the impact of denosumab as an adjuvant treatment for Stage II and Stage III breast cancer.